Immunology News and Research

Latest Immunology News and Research

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences Inc., today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit.

5 Mar 2010

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

5 Mar 2010

Gene involved in susceptibility and resistance to TB identified

University of Washington researchers have identified a gene involved in susceptibility and resistance to tuberculosis. This same gene, they have found, has a role in the severity of leprosy, which is caused by a related pathogen. The researchers also have learned why this gene is important for susceptibility.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

FDA approves CSL Behring's Hizentra for PI

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

4 Mar 2010

Boosting immune response to vaccinations: Role of aluminium adjuvants

An imminent publication in Trends in Immunology by a leading researcher in the bioinorganic chemistry of aluminium, Dr Christopher Exley, Reader in Bioinorganic Chemistry at The Birchall Centre, Keele University in Staffordshire, has now gone some way to giving the fullest possible explanation of how aluminium adjuvants work in boosting the immune response to vaccination.

4 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

FDA's recommendations over LABAs: AANMA advises patients to make informed decisions

Allergy & Asthma Network Mothers of Asthmatics (AANMA) encourages patients to make informed decisions about recent U.S. Food and Drug Administration (FDA) recommendations affecting patients using asthma medications known as long-acting beta agonists (LABAs) or 12-hour bronchodilators: Advair, Foradil, Serevent and Symbicort.

3 Mar 2010

Majority of PI patients can be switched to IgPro20 without dose adjustment

Data from a European multicenter (non-IND study) showing that patients with PI who switched to IgPro20 from previously available SCIg formulations achieved comparable IgG trough levels without dosage adjustment, resulting in significantly less administration volume. The data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in New Orleans, US.

3 Mar 2010

Step-up treatments may benefit children with asthma on low-dose inhaled corticosteroids

Children with asthma who continue to have symptoms while using low-dose inhaled corticosteroids could benefit from increasing the dosage or adding one of two asthma drugs, a new study by researchers at Washington University School of Medicine and other institutions finds.

3 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Study: LABA can be effective step-up treatment for children whose asthma is not well controlled

For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments. National Jewish clinician-scientists Stanley Szefler, Joseph Spahn, Ronina Covar Gary Larsen and Lynn Taussig, and colleagues in the NIH-funded Childhood Asthma Research and Education Network published their findings March 2, 2010, online in the New England Journal of Medicine.

3 Mar 2010

Data demonstrating effectiveness of KALBITOR to treat acute HAE presented at AAAAI 2010 Annual Meeting

Data demonstrating the effectiveness of KALBITOR (ecallantide) to treat hereditary angioedema (HAE) acute attacks by primary attack location were provided in an oral presentation yesterday at the American Academy of Allergy, Asthma and Immunology 2010 Annual Meeting in New Orleans.

3 Mar 2010

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the signing of a License and Supply Agreement with Kyowa Hakko Kirin that provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Taiwan, Hong Kong, Singapore and Malaysia.

3 Mar 2010

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

2 Mar 2010

Stress increases resistance to influenza infection

A new study using mice suggests that a repeated stressful situation that triggers the animals' natural "fight-or-flight" response may actually enhance their ability to fight disease when re-exposed to the same pathogen.

2 Mar 2010

C1-INH replacement therapy effective for treating acute swelling attacks in HAE

C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Additional pharmacokinetic data presented at the meeting confirms that C1-INH concentrate has a longer half-life than other treatment options for HAE, which protects patients from rebound attacks.

2 Mar 2010

Patients with HAE experience prodromal symptoms before acute HAE attacks: Survey

Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology Annual Meeting.

2 Mar 2010

Immunology News and Research

Latest Immunology News and Research

YM Biosciences to raise $15M in registered direct offering of common stock

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Gene involved in susceptibility and resistance to TB identified

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

FDA approves CSL Behring's Hizentra for PI

Boosting immune response to vaccinations: Role of aluminium adjuvants

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

FDA's recommendations over LABAs: AANMA advises patients to make informed decisions

Majority of PI patients can be switched to IgPro20 without dose adjustment

Step-up treatments may benefit children with asthma on low-dose inhaled corticosteroids

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Study: LABA can be effective step-up treatment for children whose asthma is not well controlled

Data demonstrating effectiveness of KALBITOR to treat acute HAE presented at AAAAI 2010 Annual Meeting

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

Phase III study results of Merck's allergy immunotherapy tablet

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Stress increases resistance to influenza infection

C1-INH replacement therapy effective for treating acute swelling attacks in HAE

Patients with HAE experience prodromal symptoms before acute HAE attacks: Survey

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey